國立高雄大學圖資館 |

Language: English

Back to Search results for [ subject:"Antidepressants." ]

Melatonin, neuroprotective agents an...

Lopez-Munoz, Francisco.

Melatonin, neuroprotective agents and antidepressant therapy

Record Type:	Electronic resources : Monograph/item
Title/Author:	Melatonin, neuroprotective agents and antidepressant therapyedited by Francisco Lopez-Munoz ... [et al.].
other author:	Lopez-Munoz, Francisco.
Published:	New Delhi :Springer India :2016.
Description:	xxv, 921 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Melatonin.
Online resource:	http://dx.doi.org/10.1007/978-81-322-2803-5
ISBN:	9788132228035$q(electronic bk.)

Melatonin, neuroprotective agents and antidepressant therapy
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /edited by Francisco Lopez-Munoz ... [et al.]. - New Delhi :Springer India :2016. - xxv, 921 p. :ill., digital ;24 cm.

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.

ISBN: 9788132228035$q(electronic bk.)

Standard No.: 10.1007/978-81-322-2803-5doiSubjects--Topical Terms:

649179
Melatonin.

LC Class. No.: RM297.M44

Dewey Class. No.: 615.78

Melatonin, neuroprotective agents and antidepressant therapy
LDR:02491nmm a2200301 a 4500 001 500075
003 DE-He213
005 20161117101939.0
006 m d
007 cr nn 008maaau
008 170621s2016 ii s 0 eng d
020 $a 9788132228035$q(electronic bk.)
020 $a 9788132228011$q(paper)
024 7 $a 10.1007/978-81-322-2803-5 $2 doi
035 $a 978-81-322-2803-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM297.M44
072 7 $a MJN $2 bicssc
072 7 $a MED056000 $2 bisacsh
082 0 4 $a 615.78 $2 23
090 $a RM297.M44 $b M517 2016
245 0 0 $a Melatonin, neuroprotective agents and antidepressant therapy $h [electronic resource] / $c edited by Francisco Lopez-Munoz ... [et al.].
260 $a New Delhi : $b Springer India : $b Imprint: Springer, $c 2016.
300 $a xxv, 921 p. : $b ill., digital ; $c 24 cm.
520 $a This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
650 0 $a Melatonin. $3 649179
650 0 $a Melatonin $x Therapeutic use. $3 678745
650 0 $a Antidepressants. $3 252255
650 0 $a Medicine. $3 193819
650 0 $a Internal medicine. $3 306407
650 0 $a Neurology. $3 211583
650 0 $a Psychopharmacology. $3 252258
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Internal Medicine. $3 273839
700 1 $a Lopez-Munoz, Francisco. $3 763254
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-81-322-2803-5
950 $a Medicine (Springer-11650)